Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Progen Pharmaceuticals scales back manufacturing and drug discovery divisions
April 2008
SHARING OPTIONS:

BRISBANE, Australia—Australian drug company Progen Pharmaceuticals has restructured its manufacturing and drug discovery divisions to conserve current cash reserves for driving present and future Progen lead compounds toward commercialization. Progen will outsource the commercial manufacture of PI-88 within the next 12 to 18 months and retain its manufacturing facility in Darra as a stand-alone business providing process development services and the manufacture of drug development material.

"The facility was never designed for the manufacture of commercial quantities, and we intend to contract out commercial PI-88 production to an established large-scale commercial bio-pharmaceutical manufacturer," says Progen CEO Justus Homburg.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.